Immix Biopharma Further Expands U.S. Clinical Sites for relapsed/refractory AL Amyloidosis Trial NEXICART-2
Provided By GlobeNewswire
Last update: May 23, 2025
– Patient enrollment exceeding expectations –
– 14 U.S. sites actively enrolling; 10 U.S. sites added since last update –
– Anticipate completing NEXICART-2 clinical trial ahead of schedule –
Read more at globenewswire.com2.4
+0.05 (+2.13%)
Find more stocks in the Stock Screener
IMMX Latest News and Analysis
18 days ago - ChartmillThe trading volume of these stocks is deviating from the norm in today's session.Let's have a look at what is happening on the US markets on Thursday. Below you can find the stocks with an unusual volume in today's session.
20 days ago - ChartmillOn Tuesday, there are stocks with unusual volume. Let's take a look.Join us as we delve into today's session and uncover the stocks that are standing out with unusual volume.
